Alternate-site pacing as monotherapy for prevention of atrial fibrillation: Is it here to stay?

Journal of Cardiovascular Electrophysiology

Volumn 12, Issue 8, 2001, Pages 918-920

  Saksena, Sanjeev ^a,d   Filipecki, Artur ^b,c  

^a Atlantic Health   (United States)

^b Robert Wood Johnson   (United States)

^c Electrophysiology Research Foundation   (United States)

^d Cardiac Medicine and EP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART PACING; HEART RIGHT ATRIUM; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; SHORT SURVEY;

EID: 0034881720     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.2001.00918.x     Document Type: Short Survey

References (26)

1. Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing for sick sinus syndrome
2. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes
3. The Mode Selection Trial (MOST) in sinus node dysfunction: Design, rationale, and baseline characteristics of the first 1000 patients
4. Control of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine
5. The dual site atrial pacing for permanent atrial fibrillation trial: Improved suppression of drug refractory atrial fibrillation with dual site atrial pacing and antiarrhythmic drugs
6. Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's bundle: Results of a multicenter randomized trial
7. Regional right and left atrial activation patterns during single- and dual-site atrial pacing in patients with atrial fibrillation
8. Acute effects of dual-site right atrial pacing in patients with spontaneous and inducible atrial flutter and fibrillation
9. Prevention of the initiation of atrial fibrillation: Mechanism and efficacy of different atrial pacing modes
10. Classification of atrial fibrillation
11. Characterization of different subsets of atrial fibrillation in general practice in France: The ALFA study
12. Definitions and endpoints for device clinical trials in atrial fibrillation: A pressing need
13. Don't you agree, or what part of the problem don't you understand?
14. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: The AIDA study
15. Reduction in frequency of atrial tachyarrhythmia episodes using novel prevention algorithms of an atrial pacemaker defibrillator
16. Progression of permanent atrial fibrillation after atrioventricular junction ablation and dual-chamber pacemaker implantation in patients with paroxysmal atrial fibrillation
17. Randomized crossover comparison of DDDR versus VDD pacing after atrioventricular junction ablation for prevention of atrial fibrillation
18. Distribution of patients' paroxysmal atrial tachyarrhythmia episodes: Implications for detection of treatment efficacy
19. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention
20. Electrical storm presages nonsudden death: The Antiarrhythmics Versus Implantable Defibrillators (AVID) trial
21. Interpretation of antiarrhythmic clinical trials: Design features and population impact
22. Dual Site Atrial Pacing for Prevention of Atrial Fibrillation [DAPPAF] Trial: Echocardiographic evaluation of atrial and ventricular function during a randomized trial of support, high right atrial and dual site right atrial pacing
23. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation. A randomized controlled study
24. Interatrial septal pacing: A new approach to prevent recurrent atrial fibrillation